A committee of scientific advisors to the U.S. Food and Drug Administration voted Friday overwhelmingly to reject a booster dose of the Pfizer-BioNTech COVID-19 vaccine for people at least 16-years-old. The advisors, however, unanimously recommended a coronavirus vaccine booster for those 65-years-old and up or at high risk for developing complications.
The 16-to-3 vote on boosters for everyone came after a full day of public discourse on whether a third shot is needed. President Joe Biden hoped the FDA would approve the third injection by this week, meeting his timeline to begin administering them on September 20.
The panel unanimously consented on boosters for senior citizens and people at high risk.
Pfizer representatives, the Centers for Disease Control and Prevention, the Israeli government, and other experts joined hours of presentations.
The panel of scientists debated whether the data supports a widespread deployment of a third injection when evidence shows that fully vaccinated patients still have protection from severe illness and hospitalization.
“It’s unclear that everyone needs to be boosted, other than a subset of the population that clearly would be at high risk for serious disease,” committee member and NIH official Dr. Michael G. Kurilla affirmed.
Several of the panel’s members have argued there is no reliable data to support boosters.
The FDA is not required to adhere to the panel’s vote, but it traditionally respects their advice. The agency will likely publish its final decision in the coming week. Then, the CDC will then meet to plan the logistics of a potential rollout.
Despite the Biden administration’s timeline, FDA and CDC officials warned him there would not be full approval of both vaccines’ boosters before next week.
Israeli scientists said booster shots “actually saved lives,” claiming the third injection helped avoid a fourth wave of the virus and cut the number of severe infections in half.
Other committee members—doubtful of their conclusions—questioned if the U.S. would be better off waiting for a booster vaccine specifically designed to block the COVID-19 Delta variant.